KÜÇÜK HÜCRELİ DIŞI AKCİĞER KANSERİ OLGULARINDA PET/BT'DEKİ PRİMER TÜMÖR SUVMAX DEĞERİNİN PROGNOSTİK DEĞERİ VE UZAK ORGAN, LENF NODU METASTAZI İLE İLİŞKİSİ
Amaç: Çalışmamızda Küçük hücreli dışı akciğer kanserli (KHDAK) olgularda, tedavi öncesi Floro deoksi glikoz-Pozitron Emisyon Tomografi ve Bilgisayarlı Tomografi'de (FDG-PET/BT) SUVmax (standart uptake value) değerinin; sağkalım ile korele olup olmadığını belirlemek ve primer tümör SUVmax değerinin uzak organ ya da lenf bezi metastazı ile ilişkisini araştırmayı amaçladık. Yöntem ve Gereç: Ocak 2010-Aralık 2013 tarihleri arasında İzmir Dr. Suat Seren Göğüs Hastalıkları ve Cerrahisi Eğitim Araştırma Hastanesi 2. serviste yeni tanı konulan ve evrelemesinde FDG-PET/BT kullanılan 208 KHDAK'li olgunun dosyaları retrospektif olarak incelendi. Olguların dosyalarından hastaların cinsiyet, yaş, sigara öyküsü, performans durumu, tanı tarihi, histolojik tipi, evresi, ilk progresyon tarihi, ölüm tarihi ve kitle, lenf nodu ve metastaz gelişmiş odağın FDG-PET/BT'deki SUVmax değerleri SPSS programına kaydedildi. Bulgular: T SUVmax ortalama değeri erkeklerde ve tümör çapı 5 cm üzerinde olanlarda anlamlı derecede yüksek bulundu (sırasıyla p:0,025 ve p:0,001). Tümör tipi adenokanser olanlarda T SUVmax değeri anlamlı düzeyde düşük saptandı (p:0,01).T SUVmax değeri ile evre ve tümörün yerleşim yeri olan periferik ya da santral olması arasında istatistiksel olarak anlamlı fark saptanmadı (sırasıyla p:0,0530, p: 0,0902).T SUVmax ortalaması T1 olanlarda istatistiksel olarak anlamlı düzeyde düşük (p:0,011)saptanırken, T4 olanlarda ise istatistiksel olarak anlamlı düzeyde yüksek bulundu (p:0,019). N ve M faktörü ile T SUVmax değeri arasında istatistiksel olarak anlamlı fark saptanmadı (p>0,05). Primer tümör T SUVmax değeri, sağ kalan hastalarda 15,03±6,07 iken ölen hastalarda ise 15,33±6,50 idi. Sağ kalan ve ölen hastalar ile primer tümör T SUVmax ortalama değeri arasında istatistiksel olarak anlamlı fark saptanmadı (p:0,74) Sonuç: Bu çalışma, KHDAK'lı olguların, sağkalım süresinde FDG-PET/BT'deki primer tümör SUVmax değerinin önemli rolü olmadığını düşündürtmüştür.
PROGNOSTIC IMPORTANCE OF SUV MAX VALUE IN PET/CT AND CORRELATION SUV MAX VALUE BETWEEN LYMPH NODE, DISTANT METASTASIS IN NON SMALL CELL LUNG CANCER
Aim: In our study, we aimed to investigate the correlation between the SUVmax value of pretreatmentFDG- PET/CT and survival and to determine whether the SUVmax value of primary tumor correlates with distant organs or lymph node metastases in non-small cell lung cancer (NSCLC) patients. Material and Methods: Between January 2010- December 2013 newly diagnosed and scanned with FDG-PET/CT 208 NSCLC patients were analyzed retrospectively at İzmir Dr. Suat Seren Göğüs Hastalıkları Cerrahisi Eğitim Araştırma Hastanesi, 2nd chest diseases clinic. From the files of the cases patients's sex,age,smoking history, performance status,date of diagnosis, histological type,stage,first progression date, death date and FDG-PET/CT SUVmax values of the primary tumor,lymph node and metastases were recorded in the SPSS. Survival time was defined as;between the date of diagnosis and the date of death searched from Mernis System or the last application date to us whether patient is alive. Results: T SUVmax values were significantly higher in men and tumor size greater than 5 cm (p:0,025 and p: 0,001).T SUVmax value was significantly lower in Adenocarcinoma (p:0,01). There was no statistically significant difference between T SUVmax value and the stage and tumor localization (p:0,0530, p:0,0902) TSUVmax value were found statistically significantly lower in T1 patients (p =0.011) than in T4 patients (p=0.019). There was no statistically significant difference between N and M factor and T SUVmax values (p> 0.05).T SUVmax value was 15,03±6,07 and 15.33±6.50 in alive, death patients respectively. There was no difference between T SUVmax value and alive, death patients (p=0.74). Conclusion: It was considered that SUVmax does not play an important role in the survival period of NSCLC patients.
___
- 1. Shields TW. Surgical Treatment of
nonsmall cell lung cancer. General
Thoracic Surgery. Lippincott, Williams
and Wilkins 2000:1311-41.
- 2. Gail Darling, Carolyn M. Dresler. Clinical
Presentation of Lung Cancer in Thoracic
Surgery. Churchill Livingstone Inc. ed.
F.G.Pearson; 96:1269-1271.
- 3. Beckles MA, Spiro SG, Colice GL, Rudd
RM. Initial evaluation of the patient with
lung cancer: symptoms, signs, laboratory
tests and paraneoplastic syndromes.
Chest 2003;123: 97-104.
- 4. Brundage MD, Davies D. Mackillop WJ.
Prognostic factors in non-small cell lung
cancer: a decade of progress. Chest
2002;122:1037-57.
- 5. Bury T, Dowlati A, Paulus P. Whole-body
18FDG positron emission tomography in
the staging of non-small cell lung cancer.
Eur Respir J 1997:10; 2529-34.
- 6. Brink I, Reinhardt J, Hoegerle S,
Altehoefer C, Ernst Moser, Egbert U.
Increased metabolic activity in the thymus
gland studied with 18F-FDG PET: Age
dependency and frequency after
chemotherapy. J Nucl Med 200;42: 591-5.
- 7. Patz EF Jr, Connolly J, Herndon J.
Prognostic value of thoracic FDG PET
imaging after treatment for non-small cell
lungcancer. Am J Roentgenol 2000; 174:
769-74.
- 8. Hellwig D, Gröschel A, Graeter TP, Hellwig
AP, Nestle U, SchafersHJ. Diagnostic
performance and prognostic impact of
FDG-PET in suspected recurrence of
surgically treated nonsmall cell lung
cancer. Eur J NuclMed Mol Imaging 2006;
33:13-21.
- 9. Vesselle H, Freeman JD, Wiens L, Stern J,
Nguyen HQ, HawesSE. Fluorodeoxy glucose
uptake of primary non-smallcell lung
cancer at positron emission tomography:
new contrary data on prognostic role. Clin
Cancer Res 2007; 13: 3255-63.
- 10. Cerfolio RJ, Bryant AS, Ohja B, Bartolucci
AA. The maximum standardized uptake
values on positron emission tomography
of a non-small cell lung cancer predict
stage, recurrence, andsurvival. J Thorac
Cardio vasc Surg 2005; 130: 151-9.
- 11. Downey RJ, Akhurst T, Gonen M, Park B,
Rusch V. Fluorine-18 fluorodeoxy glucose
positron emission tomographic
maximalstandardized uptake value
predicts survival independen tof clinical
but not pathologic TNM staging of
resected nonsmallcell lung cancer. J
Thorac Cardiovasc Surg 2007; 133:1419-
1427, doi: 10.1016/j.jtcvs.2007.01.041
- 12. Berger KL, Nicholson SA, Dehdashti F,
Siegel BA. FDG PET evaluation of
mucinous neoplasms: correlation of FDG
uptake with histopathologic features. Am
J Roengenol 2000; 174: 1005-8.
- 13. Chen JC, Huang TW, Cheng YL, Chang H,
Tzao C, Huang WS, et al. Prognostic value
of 18-FDG uptake in early stage NSCLC.
Thorac Cardiovasc Surg 2009; 57: 413-
416, doi: 10.1055/s-0029-1185733.
- 14. Lu P, Yu L, Li Y, Sun Y. A correlation study
between maximum standardized uptake
values and pathology and clinical staging
in nonsmall cell lung cancer. Nucl Med
Commun 2010; 31: 646-651.
- 15. Berghmans T, Dusart M, Paesmans M.
Primarytumorstandardizeduptakevalue
(SUVmax) measured on
fluorodeoxyglucose positron emission
tomography (FDG-PET) is of prognostic
value for survival innon-small cell lung
cancer: a systematic review and metaanalysis
by the European Lung Cancer
Working Party for the IASLC Lung Cancer
Staging Project. J Thorac Oncol 2008; 3:
6–12.
- 16. Hoang JK, Hoagland LF, Coleman RE,
Coan AD, Herndon JE II, Patz EF Jr.
Prognostic value of fluorine-18
fluorodeoxyglucose positron emission
tomography imaging in patients with
advanced-stage non-small cell lung
carcinoma. J Clin Oncol 2008; 26: 1459-
64.
- 17. Sugawara Y, Quint LE, Iannettoni MD,
Orringer MB, Russo JE, Recker BE, Saran
PA, Wahl RL. Does the FDG uptake of
primary non-small cell lung cancer
predict prognosis? A work in progress.
Clin Positron Imag 1999; 2(2):111-8.
- 18. Erdem V, Selimoğlu Şen H, Kömek H,
Tanrıkulu ÇA, Abakay A, Sezgi C, Kaya H,
Şenyiğit A. Küçük hücreli dışı akciğer
kanseri olan olgularda prognostik faktörler
ve PET/BT’deki SUVmax değerinin
prognostik önemi. Tuberk Toraks 2012;
60(3): 207-217.
- 19. Paesmans M, Berghmans T, Dusart M,
Garcia C, Hossein-Foucher C, Lafitte JJ.
Primary tumor standardized uptake value
measured on fluorodeoxyglucose positron
emission tomography is of prognostic
value for survival in non-small cell lung
cancer: Update of a Systematic Review
and Meta-Analysis by the European Lung
Cancer Working Party for the International
Association for the Study of Lung Cancer
Staging Project. J Thorac Oncol 2010; 5:
612-9.
- 20. Nael S, Kathy G, Julie L, Rashid A, Kishore
D, Lorraine W, Eillish M, Vincent Y.
Clinical implication and prognostic
significance of standardised uptake value
of primary non-small cell lung cancer on
positron emissıon tomography: analysis
of 176 case .European Journal of Cardiothoracic
Surgery 2008; 34 : 892—897.
- 21. Ahuja V, Coleman RE, Herndon J, Patz EF
Jr. The prognostic significance of
fluorodeoxyglucose PET imaging for
patients with nonsmall cell lung
carcinoma. Cancer 1998; 83: 918-24.
- 22. Mery CM, Pappas AN, Burt BM, Bueno R,
Linden PA, Sugarbaker DJ. Diameter of
non-small cell lung cancer correlates with
long-term survival: implications for T
stage. Chest 2005; 128: 3255-60.
- 23. Brown RS, Leung JY, Kison PV, Zasadny
KR, Flint A, Wahl RL. Glucose transporters
and FDG uptake in untreated primary
human non-small cell lung cancer. J Nucl
Med 1999; 40: 556-65.
- 24. Dooms C, van Baardwijk A, Verbeken E,
van Suylen RJ, Stroobants S, De
Ruysscher D. Association between 18Ffluoro-2-deoxy-D-glucose
uptake values
and tumor vitality: prognostic value of
positron emission tomography in earlystage
non-small cell lung cancer. J
Thorac Oncol 2009; 4: 822-8.
- 5. Li M, Liu N, Hu M, Shi F, Yuan S, Zhang P.
Relationship between primary tumor
fluorodeoxyglucose uptake and nodal or
distant metastases at presentation in T1
stage nonsmall cell lung cancer. Lung
Cancer 2009; 63: 383-6.
- 26. Peio Lu, Yajuan Sun ,Yanqin Sun, Lijuan
Yu. The role of FDG-PET/CT for evoluation
of metastatic mediastinal lymph nodes in
patient with lung squamous –cell
carcinoma or adenocarsinoma. Lung
Cancer 2014; 85 (2): 53-58.
- 27. Özgül MA, Kırkıl G, Ekrem Cengiz Seyhan,
Çetinkaya E,Özgül G, Yüksel M. The
maximum standardized FDG uptake on
PET CT In patients with non-small cell
lung cancer. Multidisciplinary Respiratory
Medicine 2013; 8: 69.
- 28. Soret M, Bacharach SL, Buvat I. PartialVolume
Effect in PET Tumor Imaging. J
Nucl Med 2007; 48: 932-45.
- 29. Aquino SL, Halpern EF, Kuester LB,
Fischman AJ. FDG-PET and CT features of
non-small cell lung cancer based on
tumor type. Int J Mol Med 2007; 19: 495-
9.
- 30. Eschmann SM, Friedel G, Paulsen F,
Reimold M, Hehr T, Budach W. Is
standardised (18)F-FDG uptake value an
outcome predictor in patients with stage
III non-small cell lung cancer? Eur J Nucl
Med Mol Imaging 2006; 33: 263-9.
- 31. Chong S, Lee KS, Kim BT, Choi JY, Yi CA,
Chung MJ. Integrated PET/CT of
pulmonary neuroendocrine tumors:
diagnostic and prognostic implications.
Am J Roentgenol 2007; 188: 1223-31.